RESUMO
It is known that NB-UVB therapy can suppress a broad range of immune cells, but the additional effect of bathing in geothermal seawater still remains unclear. To study the influence of treatment on the expression of circulating immune cells contributing to the pathogenesis of psoriasis, six patients with psoriasis were treated with bathing in geothermal seawater two times daily combined with NB-UVB five times/week for 2 weeks and six patients were treated with NB-UVB therapy three times/week for 8 weeks. Disease severity (Psoriasis Area and Severity Index, PASI), chemokines, inflammatory cytokines, T cells and Toll-like receptors in the blood and skin samples were evaluated on enrolment (W0) and at 1 (W1), 3 (W3) and 8 (W8) weeks. Compared with healthy controls, psoriasis patients with active disease had significantly higher proportion of peripheral CLA+ T cells expressing CCR10 and CD103 and T cells with both Th1/Tc1 (CD4+/CD8+ IFN-γ+ or TNF-α+ cells) and Th17/Tc17 (CD4+CD45R0+IL-23R+, CD4+/CD8+ IL-17A+ or IL-22+ cells) phenotypes. Both treatments gave a significant clinical effect; however, bathing in geothermal seawater combined with NB-UVB therapy was more effective than NB-UVB therapy alone. This clinical improvement was reflected by a reduction in circulating CLA+ peripheral blood T cells and by a decreased Th1/Th17 and Tc1/Tc17 inflammatory response. These findings suggest that the inflammatory response in psoriasis is predominantly driven by both CD4+ and CD8+ skin-homing tissue retaining T cells of the Th17/Tc17 lineages.
Assuntos
Banhos , Fontes Termais , Psoríase/imunologia , Psoríase/terapia , Células Th17/imunologia , Terapia Ultravioleta/métodos , Adulto , Antígenos CD/metabolismo , Linfócitos T CD8-Positivos/imunologia , Progressão da Doença , Feminino , Humanos , Cadeias alfa de Integrinas/metabolismo , Interferon gama/sangue , Interleucina-17/sangue , Interleucinas/sangue , Contagem de Linfócitos , Masculino , Pessoa de Meia-Idade , Psoríase/radioterapia , Receptores CCR10/metabolismo , Água do Mar , Pele/citologia , Pele/imunologia , Células Th1/imunologia , Receptores Toll-Like/sangue , Interleucina 22RESUMO
Resonant photon tunneling was investigated experimentally in multilayer structures containing a high-contrast (TiO(2)/SiO(2)) Bragg mirror capped with a semitransparent gold film. Transmission via a fundamental cavity resonance was compared with transmission via the Tamm plasmon polariton resonance that appears at the interface between a metal film and a one-dimensional photonic bandgap structure. The Tamm-plasmon-mediated transmission exhibits a smaller dependence on the angle and polarization of the incident light for similar values of peak transmission, resonance wavelength, and finesse. Implications for transparent electrical contacts based on resonant tunneling structures are discussed.
RESUMO
Acromegaly is usually caused by a growth hormone (GH)-secreting pituitary adenoma. In rare cases, however, it is caused by the ectopic production of growth hormone-releasing hormone (GHRH). We report a case of acromegaly due to ectopic production of GHRH from a bronchial carcinoid in a 42-year-old female. The carcinoid tumor was successfully treated with bilobectomy.
Assuntos
Acromegalia/etiologia , Neoplasias Brônquicas/metabolismo , Neoplasias Brônquicas/cirurgia , Tumor Carcinoide/metabolismo , Tumor Carcinoide/cirurgia , Acromegalia/sangue , Adulto , Neoplasias Brônquicas/sangue , Tumor Carcinoide/sangue , Feminino , Hormônio Liberador de Hormônio do Crescimento/sangue , HumanosRESUMO
BACKGROUND: BARD1 was originally identified as a BRCA1-interacting protein but has also been described in tumour-suppressive functions independent of BRCA1. Several studies have indicated that the BARD1 gene is a potential target for germline changes predisposing to breast and ovarian cancer. The C-terminal Cys557Ser change has previously been uncovered to associate with an increased risk of breast cancer and was recently shown to result in defective apoptotic activities. AIM AND METHODS: Conformation-sensitive gel electrophoresis, minisequencing, TaqMan assays, denaturing high-performance liquid chromatography analysis and DNA sequencing were used to investigate the prevalence of the Cys557Ser allele in a large Nordic case-control study cohort consisting of 2906 patients with breast or ovarian cancer, 734 with prostate cancer, 188 with colorectal cancer, 128 men with breast cancer, and 3591 controls from Finland, Iceland, Denmark, Sweden and Norway. RESULTS: The frequency of the BARD1 Cys557Ser variant seemed to increase among patients from families with breast or ovarian cancer lacking BRCA1 or BRCA2 mutations: a significant difference was obtained compared with controls (6.8% v 2.7%; p<0.001; odds ratio (OR) 2.6; 95% confidence interval (CI) 1.7 to 4.0) and with patients from BRCA1/BRCA2 mutation-positive families (6.8% v 2.2%; p = 0.01; OR 3.2; 95% CI 1.2 to 8.3). In contrast, no major association with male breast, ovarian, colorectal or prostate cancer was observed. Additionally, a novel BARD1 allele resulting in Ser558Pro was identified in familial breast cancer cases. CONCLUSION: These results provide further evidence that BARD1 Cys557Ser confers a slightly increased risk of breast cancer in women.
Assuntos
Alelos , Neoplasias da Mama/genética , Mutação de Sentido Incorreto , Proteínas Supressoras de Tumor/genética , Ubiquitina-Proteína Ligases/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias da Mama Masculina/genética , Estudos de Casos e Controles , Estudos de Coortes , Neoplasias Colorretais/genética , Análise Mutacional de DNA , Feminino , Genes BRCA1 , Genes BRCA2 , Predisposição Genética para Doença , Testes Genéticos , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Ovarianas/genética , Neoplasias da Próstata/genéticaRESUMO
BRCA1 and BRCA2 mutations confer increased risk for development of breast cancer, but a number of additional, currently largely unknown, somatic genetic defects must also accumulate in the breast epithelial cells before malignancy develops. To evaluate the nature of these additional somatic genetic defects, we performed a genome-wide survey by comparative genomic hybridization on breast cancers from 21 BRCA1 mutation carriers, 15 BRCA2 mutation carriers, and 55 unselected controls. The total number of genetic changes was almost two times higher in tumors from both BRCA1 and BRCA2 mutation carriers than in the control group. In BRCA1 tumors, losses of 5q (86%), 4q (81%), 4p (64%), 2q (40%), and 12q (40%) were significantly more common than in the control group (7-13%). BRCA2 tumors were characterized by a higher frequency of 13q (73%) and 6q (60%) losses and gains of 17q22-q24 (87%) and 20q13 (60%) as compared to the prevalence of these changes in the control group (12-18%). In conclusion, accumulation of somatic genetic changes during tumor progression may follow a unique pathway in individuals genetically predisposed to cancer, especially by the BRCA1 gene. Activation or loss of genes in the affected chromosomal regions may be selected for during tumor progression in cells lacking functional BRCA1 or BRCA2. Identification of such genes could provide targets for therapeutic intervention and early diagnosis.
Assuntos
Neoplasias da Mama/genética , Genes BRCA1 , Mutação em Linhagem Germinativa , Proteínas de Neoplasias/genética , Fatores de Transcrição/genética , Adulto , Idoso , Idoso de 80 Anos ou mais , Proteína BRCA2 , Carcinoma Ductal de Mama/genética , Deleção Cromossômica , Cromossomos Humanos Par 4 , Cromossomos Humanos Par 5 , Progressão da Doença , Feminino , Heterozigoto , Humanos , Pessoa de Meia-Idade , Hibridização de Ácido Nucleico , Polimorfismo Conformacional de Fita SimplesRESUMO
Germ-line mutation in the BRCA2 gene confers an increased risk of breast cancer. An elevation of additional genetic defects in tumors of patients with germ-line mutation in the BRCA2 gene compared with sporadic breast tumors has been reported. To evaluate the nature of the difference, we did detailed mapping of chromosomes 1p, 3p, 6q, 11, 13q, 16q, 17, and 20q, using microsatellite markers. We found that the frequency of loss of heterozygosity was similar at some chromosomal regions in the BRCA2 999del5 and sporadic tumors but significantly different at others. These others include chromosomal arms 3p, 6q, 11p, 11q, 13q, and 17p. Loss of heterozygosity mapping suggests that the same chromosome regions are involved in both tumor groups but at elevated frequencies in BRCA2 999del5 tumors. This higher frequency of genetic aberrations could pinpoint genes that selectively promote tumor progression in individuals predisposed to breast cancer due to the BRCA2 999del5 germ-line mutation. Accumulation of somatic genetic changes during tumor progression may follow a specific and more aggressive pathway of chromosome damage in these individuals.
Assuntos
Neoplasias da Mama/genética , Mapeamento Cromossômico , Marcadores Genéticos , Heterozigoto , Perda de Heterozigosidade , Proteínas de Neoplasias/genética , Deleção de Sequência , Fatores de Transcrição/genética , Proteína BRCA2 , Cromossomos Humanos , Feminino , Triagem de Portadores Genéticos , Humanos , Repetições de MicrossatélitesRESUMO
Evidence for alteration of the FHIT gene in a significant fraction of breast carcinomas has been reported, in apparent concordance with loss of heterozygosity (LOH) at chromosome region 3p14.2 in breast cancer and benign proliferative breast disease. A significantly higher frequency of LOH at the FHIT locus was reported for BRCA2-/- tumors, possibly due to misrepaired double-strand breaks at this common fragile region. To determine whether such genomic alterations lead to Fhit inactivation, we have assessed the level of Fhit expression by immunohistochemical detection in sporadic tumors and cancers occurring in BRCA2 999del5 carriers. To determine whether Fhit inactivation may have prognostic significance, we have also assessed expression of breast cancer markers and clinical features in sporadic tumors relative to Fhit expression. Of 40 consecutive sporadic breast carcinomas studied for tumor markers, 50% showed reduced Fhit expression. In these sporadic cancers, loss of Fhit expression was not correlated significantly with the presence or absence of other tumor markers. In a study of 58 sporadic and 34 BRCA2 999del5 Icelandic invasive cancers, there was a significant association of LOH at 3p14.2 with reduced expression of Fhit (P = 0.001); also the lower expression of Fhit and higher LOH at 3p14.2 in BRCA2 999del5 tumors relative to sporadic cancers was significant (P = 0.002). Thus, genetic alteration at the fragile site within the FHIT gene leads to loss of Fhit protein in a significant fraction of sporadic breast cancers and a much larger fraction of familial breast cancers with an inherited BRCA2 mutation, consistent with the idea that loss of BRCA2 function affects stability of the FHIT/FRA3B locus.
Assuntos
Hidrolases Anidrido Ácido , Neoplasias da Mama/metabolismo , Cromossomos Humanos Par 3/genética , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/metabolismo , Proteínas/metabolismo , Fatores de Transcrição/genética , Adulto , Idoso , Proteína BRCA2 , Neoplasias da Mama/genética , Feminino , Humanos , Perda de Heterozigosidade , Repetições de Microssatélites , Pessoa de Meia-Idade , Mutação , Proteínas/genéticaRESUMO
Studies on Icelandic breast cancer families have shown that most of them segregate a 999del5 BRCA2 mutation. Here, we report the frequency of the 999del5 BRCA2 mutation in an Icelandic control population and four different groups of cancer patients diagnosed with (a) breast cancer; (b) ovarian cancer; (c) prostate cancer (patients younger than 65 years); and (d) other cancer types. The proportions of individuals carrying the mutation were 0.4% in the control population and in the patient groups 8.5%, 7.9%, 2.7%, and 1.0%, respectively. Our results indicate that BRCA2 confers a very high risk of breast cancer and is responsible for a substantial fraction of breast and ovarian cancer in Iceland, but only a small proportion of other cancers.
Assuntos
Neoplasias da Mama/genética , Deleção de Genes , Proteínas de Neoplasias/genética , Neoplasias Ovarianas/genética , Fatores de Transcrição/genética , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Proteína BRCA2 , Sequência de Bases , Feminino , Humanos , Pessoa de Meia-Idade , Dados de Sequência MolecularRESUMO
Formation and quality of single solid supported lipid membranes and double lipid membranes were investigated with single vesicle resolution using label-free evanescence light scattering microscopy (EvSM). For the formation of double lipid membranes we made use of electrostatic interaction between charged lipids and oppositely charged cations.
RESUMO
Breast tumours from BRCA1 and BRCA2 mutation carriers are genetically instable and display specific patterns of chromosomal aberrations, suggestive of distinct genetic pathways in tumour progression. The frequency of abnormalities affecting chromosome 17p and the TP53 gene was determined in 27 breast tumours from 26 female patients carrying the Icelandic BRCA2 founder mutation (999del5). Loss of heterozygosity (LOH) was detected in 23 of the 27 tumours (85%). The majority of tumours manifesting LOH had lost a large region on 17p, although a more restricted loss, including the TP53 locus was seen in a few tumours. Positive p53 immunostaining was observed in 18 of 26 tumours (69%). However, mutations in the TP53 gene were detected in only three tumours (11%), including a missense (codon 139) and a nonsense mutation (codon 306) in two tumours with moderate p53 expression and a frameshift deletion (codon 182) in a tumour with no detectable p53 expression. Positive p53 immunostaining, mainly weak, was observed in 16 of the 24 tumours (66%) without TP53 mutation. The high frequency of LOH at chromosome 17p13 suggests that one or more genes from this region are involved in the development of BRCA2-induced breast cancer. The frequent finding of weak overexpression of, presumably wild type p53 protein, suggests an alternative mechanism of TP53 involvement specific to these tumours.
Assuntos
Neoplasias da Mama/genética , Cromossomos Humanos Par 17 , Heterozigoto , Perda de Heterozigosidade , Proteínas de Neoplasias/genética , Fatores de Transcrição/genética , Proteína BRCA2 , Cromossomos Humanos Par 13 , Cromossomos Humanos Par 7 , DNA Satélite , Marcadores Genéticos , Humanos , Imuno-Histoquímica , Proteína Supressora de Tumor p53/metabolismoRESUMO
Chromosomal losses involving the short arm of chromosome 8 are frequent in a variety of tumour types, including breast cancer, suggesting the presence of one or more tumour suppressor genes in this region. In this study, we have used 11 microsatellite markers to analyse loss of heterozygosity (LOH) at chromosome 8p in 151 sporadic breast tumours and 50 tumours from subjects carrying the BRCA2 999del5 mutation. Fifty percent of sporadic tumours compared to 78% of BRCA2 linked tumours exhibit LOH at one or more markers at 8p showing that chromosome 8p alterations in breast tumours from BRCA2 999del5 carriers are more pronounced than in sporadic breast tumours. The pattern of LOH is different in the two groups and a higher proportion of BRCA2 tumours have LOH in a large region of chromosome 8p. In the total patient material, LOH of 8p is associated with LOH at other chromosome regions, for example, 1p, 3p, 6q, 7q, 9p, 11p, 13q, 17p, and 20q, but no association is found between LOH at 8p and chromosome regions 11q, 16q, 17q, and 18q. Furthermore, an association is detected between LOH at 8p and positive node status, large tumour size, aneuploidy, and high S phase fraction. Breast cancer patients with LOH at chromosome 8p have a worse prognosis than patients without this defect. Multivariate analysis suggests that LOH at 8p is an independent prognostic factor. We conclude that chromosome 8p carries a tumour suppressor gene or genes, the loss of which results in growth advantage of breast tumour cells, especially in carriers of the BRCA2 999del5 mutation.
Assuntos
Neoplasias da Mama/genética , Cromossomos Humanos Par 8/genética , Perda de Heterozigosidade , Proteínas de Neoplasias/genética , Fatores de Transcrição/genética , Proteína BRCA2 , DNA de Neoplasias/análise , Feminino , Genes Supressores de Tumor , Mutação em Linhagem Germinativa , Humanos , Repetições de Microssatélites , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase/métodos , Prognóstico , Deleção de SequênciaRESUMO
The fragile histidine triad (FHIT) gene is a candidate tumour suppressor gene in breast and other cancers. We investigated deletions within the FHIT gene in lobular breast cancer and found that 16% of cases showed loss of heterozygosity (LOH) within the gene. We compared LOH within FHIT in lobular and ductal breast tumours and found a significant association between LOH at FHIT and the ductal histological type (P<0.001). To determine whether genomic alteration of the FHIT gene in lobular breast cancer leads to Fhit inactivation we have assessed the level of Fhit expression by immunohistochemical detection and determined that 27% (15 of 55) consecutive sporadic lobular tumours showed negative or reduced Fhit expression. A significant association was found between LOH at the FHIT gene and reduced Fhit expression in lobular and ductal tumours (P=0.025 and P=0.001, respectively). Thus, genetic alterations within the FHIT gene, leading to loss of Fhit protein, may play an important role in the carcinogenesis of a significant number of sporadic lobular breast cancers, even though the apparent frequency of genomic alterations within the gene is lower than in ductal breast cancer.
Assuntos
Hidrolases Anidrido Ácido , Neoplasias da Mama/genética , Carcinoma Ductal de Mama/genética , Carcinoma Lobular/genética , Perda de Heterozigosidade/genética , Proteínas de Neoplasias/genética , Proteínas/genética , Proteína BRCA2 , Feminino , Deleção de Genes , Humanos , Imuno-Histoquímica , Repetições de Microssatélites , Fatores de Transcrição/genéticaRESUMO
Several chromosome regions exhibit loss of heterozygosity (LOH) in human breast carcinoma and are thought to harbour tumour suppressor genes (TSG). At chromosome 13q, two TSGs have been identified, RB1 at 13q14 and BRCA2 at 13q12-q13. In this study, 139 sporadic breast tumours were analysed with 18 polymorphic microsatellite markers for detailed mapping of LOH at chromosome 13q and evaluation of an association with known progression factors. LOH with at least one marker was observed in 71 (51%) of the tumours analysed. The deletion mapping indicated three LOH target regions, 13q12-q13, 13q14 and 13q31-q34. LOH at chromosome 13q12-q13 was associated with low progesterone receptor content, a high S phase fraction and aneuploidy. Multivariate analysis adjusting for lymph node involvement and S phase fraction showed that patients with tumours exhibiting LOH at 13q12-q13 have a 3-4-fold increased risk of recurrence and death compared with other patients. Our results suggest there are at least three separate LOH target regions at chromosome 13q and inactivation of one or more genes at chromosome 13q12-q13 results in poor prognosis for breast cancer patients.
Assuntos
Neoplasias da Mama/genética , Cromossomos Humanos Par 13/genética , Perda de Heterozigosidade/genética , Proteínas de Neoplasias/genética , Fatores de Transcrição/genética , Aneuploidia , Proteína BRCA2 , Neoplasias da Mama/metabolismo , Mapeamento Cromossômico , Intervalo Livre de Doença , Feminino , Deleção de Genes , Humanos , Repetições de Microssatélites , Prognóstico , Receptores de Progesterona/metabolismo , Fase S/genéticaRESUMO
In this report, we analyze the clinical, morphologic, and immunologic findings of 19 patients with Ki-1+ large cell lymphoma, a recently described malignant lymphoma which is usually of T-cell phenotype. Most patients in this selected series of 14 children and adolescents and five adults presented with peripheral lymphadenopathy or skin lesions. No patient had bone marrow involvement. Distinctive morphologic features of Ki-1+ large cell lymphoma are tumor cell pleomorphism, sinus infiltration, fibrosis, partial lymph node involvement, sparing of B-cell regions, and a prominent plasma cell infiltrate. Seventy-two percent of cases were of T-cell phenotype; the remaining cases expressed neither B- nor T-cell-specific markers. Virtually all cases were positive for Ia (HLA-DR), Tac (interleukin-2 receptor), and T9 (transferrin receptor), indicating that this lymphoma is frequently a tumor of activated T-cells. We conclude that a diagnosis of Ki-1+ large cell lymphoma should be considered in any pleomorphic tumor with the features described in this report.
Assuntos
Anticorpos Monoclonais , Linfoma/patologia , Adolescente , Adulto , Idoso , Biópsia , Criança , Pré-Escolar , Feminino , Humanos , Linfonodos/imunologia , Linfonodos/patologia , Doenças Linfáticas/patologia , Linfoma/imunologia , Masculino , Pessoa de Meia-Idade , Neoplasias Cutâneas/patologia , Neoplasias de Tecidos Moles/patologia , Neoplasias Gástricas/patologiaRESUMO
Lymphomatoid papulosis (LyP) is a papulonodular skin eruption characterized by spontaneous regression. In order to evaluate the role of host immune reactions in the phenomenon of regression, we analyzed skin biopsies from various stages of evolution in 16 patients with LyP using morphologic and immunoperoxidase techniques. Both rapidly regressing type A and more chronic type B lesions of LyP had modest perivascular and lesional infiltrates of small helper and suppressor T lymphocytes as well as histiocytes. Type A lesions in addition to numerous neutrophils and eosinophils had a more extensive lymphocytic infiltrate than type B lesions. Natural killer cells were not prominent in the skin lesions, although several patients had increased numbers of circulating natural killer cells. Our results demonstrate a correlation between the inflammatory components found in skin biopsies from patients with LyP and clinical behavior and suggest that cell-mediated immune reactions may play a role in the spontaneous regression of LyP.
Assuntos
Imunidade Celular , Dermatopatias/imunologia , Adulto , Feminino , Humanos , Linfócitos/classificação , Linfoma/imunologia , Linfoma/patologia , Masculino , Dermatopatias/patologia , Linfócitos T/patologiaRESUMO
The authors conducted a histopathologic study on tissues from 11 patients with the recently described syndrome of large granular lymphocyte (LGL) leukemia. Distinctive pathologic findings were found most often in the bone marrow, liver, and spleen. The bone marrow biopsies contained nonparatrabecular lymphoid infiltrates that were nodular or diffuse and interstitial. Plasmacytosis was found and in two cases there was myeloid maturation arrest. The liver biopsies contained sinusoidal and portal infiltrates and the spleen had red pulp cord and sinus infiltrates, plasmacytosis, and follicular hyperplasia. Lymph node involvement was nondiagnostic, consistent with the usual absence of lymphadenopathy. The morphologic findings were sometimes indistinguishable from other reactive or low-grade lymphoproliferative disorders, especially chronic lymphocytic leukemia/well-differentiated lymphocytic lymphoma (CLL/WDLL) and hairy cell leukemia. These results suggest the need to correlate peripheral blood cell counts and morphology as well as immunophenotypic studies with tissue histology to distinguish LGL leukemia from other disorders. Establishing a correct diagnosis of LGL leukemia may help clarify the etiology of unexplained peripheral blood cytopenias, arthritis, and other autoimmune manifestations in individual patients.
Assuntos
Leucemia Linfoide/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Medula Óssea/patologia , Diagnóstico Diferencial , Feminino , Humanos , Imuno-Histoquímica , Leucemia de Células Pilosas/patologia , Leucemia Linfocítica Crônica de Células B/patologia , Leucemia Linfoide/sangue , Fígado/patologia , Linfonodos/patologia , Masculino , Pessoa de Meia-Idade , Baço/patologiaRESUMO
All malignant tumours of soft tissues diagnosed in Iceland between 1955 and 1988 were reviewed histologically. Of a total of 155 tumours, 129 were, on review, soft tissue sarcomas, while 26 had been erroneously diagnosed and were excluded from the study. In 25% of the tumours the original sarcoma diagnosis was changed to another sarcoma type. Malignant fibrous histiocytoma, liposarcoma and leiomyosarcoma together comprise more than half of all tumours diagnosed. Contrary to previous estimations, according to this study, the age-standardized incidence of soft tissue sarcoma in Iceland is 1.8 per 1000,000 for males and 1.6 per 100,000 per females, which is similar to incidence rates in the other Nordic countries. The majority of sarcomas were of relatively high grade. The tumours were graded using both three and four grades of malignancy. Both systems yielded prognostic information although it was not possible to detect significant differences in survival for grade I and grade II tumours when the four grade system was used. The results of this study show that the epidemiology of soft tissue sarcoma in Iceland is similar to that found in other Western countries.
Assuntos
Neoplasias de Tecidos Moles/patologia , Fatores Etários , Feminino , Humanos , Islândia , Masculino , Sistema de Registros , Neoplasias de Tecidos Moles/classificação , Neoplasias de Tecidos Moles/epidemiologiaRESUMO
The DNA ploidy status and S-phase fraction of eight adenocarcinomas of the vermiform appendix diagnosed in Iceland during 1974-1990 were analyzed by flow cytometry. Four cases were classified as Dukes' stage B2 and four cases as Dukes' stage D. Seven tumors were diploid and one was aneuploid. The DNA aneuploid tumor was the only one which metastasized outside the abdominal cavity. The S-phase fraction in general was low. The results of this study do not indicate any significant correlation between ploidy status and clinical behavior.
Assuntos
Adenocarcinoma/patologia , Apêndice , Neoplasias do Ceco/patologia , DNA de Neoplasias/análise , Adenocarcinoma/mortalidade , Adenocarcinoma Mucinoso/mortalidade , Adenocarcinoma Mucinoso/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Neoplasias do Ceco/mortalidade , Feminino , Citometria de Fluxo , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Ploidias , Fase S , Análise de SobrevidaRESUMO
The authors report an unusual B-cell lymphoma that simulated hairy cell leukemia (HCL) not only clinically but also pathologically in peripheral blood, bone marrow, and lymph node specimens. A diagnosis of lymphoma could be made only after pathologic examination of the spleen, indicating that caution should be exercised in making a primary diagnosis of HCL on bone marrow examination. Morphologically this lymphoma resembled monocytoid B-cell lymphoma (MBCL) but the immunophenotype (monoclonal Ig-kappa +, Ia+, B4+, Leu-1+, LN-2+, lambda-, Bl-, LN-1- and CALLA-) and clinical findings were more consistent with mantle zone lymphoma (MZL). Because this case demonstrates features of both MBCL and MZL, the authors suggest that these two entities may have a common histogenesis.
Assuntos
Linfócitos B , Leucemia de Células Pilosas/diagnóstico , Linfoma/diagnóstico , Idoso , Anticorpos Monoclonais , Biomarcadores Tumorais/imunologia , Medula Óssea/patologia , Humanos , Leucemia de Células Pilosas/patologia , Linfonodos/patologia , Linfoma/patologia , Masculino , Baço/patologiaRESUMO
Approximately 20% of childhood non-Hodgkin's lymphomas (HNLs) are of peripheral T-cell type. These lymphomas form a heterogeneous group of neoplasms with different clinical features and responses to therapy. By far the most common among these lymphomas is the recently described Ki-1+ large cell lymphoma (LCL), but other types of peripheral T-cell lymphomas, which may rarely occur in children, include plemorphic T-cell lymphomas resembling adult T-cell leukemia/lymphoma (ATLL), angiocentric immunoproliferative lesions (AIL), angioimmunoblastic lymphadenopathy-like T-cell lymphoma, and cutaneous T-cell lymphoma (CTCL).